Edition:
United States

Medtronic PLC (MDT.N)

MDT.N on New York Stock Exchange

86.11USD
17 Jan 2018
Change (% chg)

$0.79 (+0.93%)
Prev Close
$85.32
Open
$85.90
Day's High
$86.44
Day's Low
$85.44
Volume
1,498,538
Avg. Vol
1,463,623
52-wk High
$89.71
52-wk Low
$73.59

Latest Key Developments (Source: Significant Developments)

Medtronic plc ‍announces global launch of StealthStation ENT​
Tuesday, 12 Sep 2017 08:00am EDT 

Sept 12 (Reuters) - Medtronic Plc ::Medtronic Plc - ‍announced global launch of StealthStation ENT​.  Full Article

Medtronic announces voluntary recall of diabetes infusion sets
Monday, 11 Sep 2017 06:45am EDT 

Sept 11 (Reuters) - Medtronic Plc ::Medtronic announces voluntary recall of diabetes infusion sets.Medtronic-‍determined a component, vent membrane, in recalled infusion sets may be susceptible to being blocked by fluid during process of priming/fill-tubing​.Medtronic PLC - ‍recall is related to a certain discontinued component in infusion sets and does not include insulin pumps or glucose sensors​.Medtronic - started to inform patients worldwide of voluntary recall of specific lots of infusion sets used with all models of medtronic insulin pumps​.Medtronic - infusion sets available since April 2017 include design update of vent membrane which co believes reduces risk of insulin over-delivery.Medtronic plc - ‍voluntary recall of infusion sets is not expected to impact diabetes group revenue growth in q2 or full fiscal year​.Medtronic plc - ‍ majority of cost due to recall of infusion sets is expected to be incurred in q2.Medtronic plc - cost of recall is not expected to impact earnings per share guidance in q2 or full fiscal year.  Full Article

Medtronic announces Japanese regulatory approval for IN.PACT Admiral drug-coated balloon
Friday, 8 Sep 2017 07:00am EDT 

Sept 8 (Reuters) - Medtronic Plc :Medtronic announces japanese regulatory approval for the IN.PACT Admiral drug-coated balloon.Medtronic Plc - ‍received approval from japanese ministry of health, labour and welfare for treatment of peripheral artery disease in upper leg​.Medtronic - ‍before co can begin commercialization, it must partner with Japanese MHLW to gain reimbursement to ensure broader access to the therapy​.  Full Article

Medtronic launches long term clinical study program of infuse bone graft in 2 common spine procedures PLF, TLIF
Tuesday, 5 Sep 2017 09:00am EDT 

Sept 5 (Reuters) - Medtronic Plc ::Medtronic launches long term clinical study program of infuse bone graft in two common spine procedures: PLF and TLIF.Medtronic Plc - PLF pilot dosing study, which will include approximately 125 patients, will be followed by a TLIF pilot dosing study in 2018.  Full Article

Medtronic Q1 non-gaap earnings per share $1.12
Tuesday, 22 Aug 2017 06:45am EDT 

Aug 22 (Reuters) - Medtronic Plc ::Reg-Medtronic reports first quarter financial results.Q1 non-gaap earnings per share $1.12.Q1 gaap earnings per share $0.74.Q1 earnings per share view $1.08 -- Thomson Reuters I/B/E/S.Medtronic Plc - ‍rtg worldwide q1 revenue of $1.809 billion increased 2 percent on both a reported and constant currency basis​.Qtrly ‍revenue of $7.390 billion grew 3 pct as reported; 4 pct at constant currency​.Medtronic - ‍spine Q1 revenue of $649 million increased 1 percent on both a reported and constant currency basis​.Medtronic - ‍in fiscal year 2018, co expects diluted non-gaap eps growth to be in range of 9 to 10 percent on a comparable, constant currency basis​.Medtronic - ‍company reiterates full year revenue and eps guidance​.Medtronic - ‍CVG Worldwide q1 revenue of $2.646 billion increased 5 percent, or 6 percent on a constant currency basis​.Fy2018 earnings per share view $4.80, revenue view $29.55 billion -- Thomson Reuters I/B/E/S.Medtronic - ‍"expect to see increasing momentum coming from several new product launches over balance of fiscal year​".Fy2018 revenue view $29.55 billion -- Thomson Reuters I/B/E/S.Medtronic -‍ 2018 non-gaap eps would be affected by about negative $0.03 to positive $0.01, including about $0.00 to positive $0.02 impact in q2.Q1 revenue view $7.45 billion -- Thomson Reuters I/B/E/S.  Full Article

Medtronic receives CE mark for Attain Stability Quad MRI SureScan active-fixation heart lead
Monday, 21 Aug 2017 12:00pm EDT 

Aug 21 (Reuters) - Medtronic plc ::Medtronic receives CE mark for Attain Stability(TM) Quad MRI SureScan(TM) active-fixation heart lead.Medtronic also ‍has initiated global non-randomized, multicenter clinical study to evaluate safety, effectiveness of heart lead​ in heart failure patients.Study will enroll up to 471 patients across 56 sites in United States, Canada, Europe, Hong Kong and Malaysia​.  Full Article

Medtronic to evaluate one-month dual antiplatelet therapy​ in ‍a global clinical trial
Monday, 14 Aug 2017 09:30am EDT 

Aug 14 (Reuters) - Medtronic plc ::Announces ‍a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy​.Resolute Onyx one-month DAPT study will enroll up to approximately 2,000 patients at approximately 70 sites​.Will evaluate DAPT ‍in patients implanted with Resolute Onyx(TM) Drug-Eluting Stent (DES) during percutaneous coronary intervention​.  Full Article

Medtronic gets FDA approval, CE Mark for Avalus Surgical Aortic Valve
Wednesday, 2 Aug 2017 10:01am EDT 

Aug 2 (Reuters) - Medtronic Plc ::Medtronic expands heart valve portfolio with FDA approval and CE Mark of the Avalus surgical aortic valve.Says Avalus Valve will be commercially available later this year.  Full Article

Medtronic Canada receives Health Canada licence for MRI conditional cardiac resynchronization therapy defibrillators
Wednesday, 26 Jul 2017 09:30am EDT 

July 26 (Reuters) - Medtronic Canada::Received Health Canada licence for, is launching MRI conditional cardiac resynchronization therapy defibrillators for heart failure.  Full Article

Medtronic plc says ‍in June of 2017 company experienced a disruption in its information technology systems - SEC filing​
Tuesday, 18 Jul 2017 06:55am EDT 

July 18 (Reuters) - Medtronic Plc :Medtronic plc - for fiscal year 2018, company reiterates its expectation that its constant currency revenue growth will be in range of 4 to 5 percent.Medtronic - ‍in Form 10-K filed with SEC on June 27, co reported that its information technology systems had been fully restored​.Medtronic - for FY 2018, company reiterates adjusted diluted EPS growth will be in range of 9 to 10 percent on a constant currency basis.Medtronic says ‍company did not believe its fiscal year 2018 results of operations or financial condition would be materially affected by incident​.Medtronic - ‍company expects growth at lower end of range in Q1​.Medtronic - ‍reiterates guidance range for adjusted earnings per share growth for fiscal Q1 of 2018 at upper end of high-single digit range on a constant currency basis​.FY2018 earnings per share view $4.95, revenue view $31.12 billion -- Thomson Reuters I/B/E/S.Medtronic - ‍reiterates its prior guidance range for both fiscal Q1 and full year revenue growth on a constant currency basis in range of 4 to 5 percent​.Medtronic - ‍fiscal year 2018 outlook does not include impact of divestiture of a portion of its patient monitoring and recovery division​.Medtronic - ‍given its disruption, strong new product demand in Diabetes Group versus temporarily limited supply of sensors, sees revenue growth at lower end of Q1​ range.FY2018 revenue view $31.12 billion -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Medtronic Receives FDA Clearance For Riptide Aspiration System

* MEDTRONIC RECEIVES FDA CLEARANCE FOR RIPTIDE(TM) ASPIRATION SYSTEM